Search

Search Constraints

You searched for: Author/Creator Marttila, Timo

Search Results

1. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. (3rd August 2022)